{"id":"W4313247961","doi":"10.2147/cmar.s340719","title":"Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management","year":2022,"lang":"en","type":"review","venue":"Cancer Management and Research","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Neoadjuvant therapy; Pancreatic cancer; Oncology; Radiation therapy; Adenocarcinoma; Pancreatic ductal adenocarcinoma; Chemotherapy; Randomized controlled trial; Clinical trial; Internal medicine; Cancer; Irinotecan; Breast cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006018485,0.000625305,0.001772905,0.001586904,0.001017255,0.004039186,0.001416591,0.002277532,0.003025363],"category_scores_gemma":[0.01721593,0.0002349848,0.0009606676,0.001473716,0.001663187,0.00546123,0.002182008,0.004937158,0.00159668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001583872,"about_ca_system_score_gemma":0.004684872,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001300424,"about_ca_topic_score_gemma":0.002942576,"domain_scores_codex":[0.9972537,0.001215638,0.0004666597,0.0002828618,0.0006452691,0.0001358301],"domain_scores_gemma":[0.9864883,0.00660348,0.001947991,0.0003317461,0.003517791,0.001110622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002348364,0.0001219317,0.005442777,0.01438349,0.0001987471,0.001213782,0.0005414939,0.0008679909,0.0008104063,0.006674255,0.1042826,0.8652278],"study_design_scores_gemma":[0.0001825418,0.0005643147,0.01272256,0.07015211,0.0006710983,0.01310566,0.007881183,0.001753097,0.0005778719,0.07042263,0.8217096,0.0002573175],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002478954,0.865364,0.003823008,0.1219647,0.002475454,0.00004895982,0.0001587009,0.00007552452,0.003610757],"genre_scores_gemma":[0.04588301,0.8970938,0.01538174,0.02524243,0.01465807,0.0001708443,0.0004667306,0.00005434494,0.001049016],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006018485,"threshold_uncertainty_score":0.03182918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5196987092176054,"score_gpt":0.5955855729175834,"score_spread":0.07588686369997799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}